论文部分内容阅读
目的:探讨SHP-1和JAK1基因在初治急性白血病(AL)细胞的转录表达及其与初治AL患者化疗效果的关系。方法:采用半定量逆转录-聚合酶链反应(RT-PCR)方法检测60例初治AL患者骨髓单个核细胞及20例健康人外周血单个核细胞中SHP-1和JAK1 mRNA的表达。结果:60例初治AL患者SHP-1和JAK1的mRNA表达阳性率分别为30%,100%;初治AL患者SHP-1 mRNA表达水平明显低于正常对照组(P<0.001),JAK1 mRNA表达水平较正常对照组略增高,但差异无统计学意义(P=0.180),初治AL患者SHP-1 mRNA阳性组的诱导化疗完全缓解(CR)率为88.9%,阴性患者组CR率为54.8%,差异有统计学意义(P=0.005)。SHP-1与JAK1 mRNA表达呈负相关(P=0.046)。结论:SHP-1可能是白血病潜在的抑制基因,可望作为判断初治急性白血病患者疗效和预后的指标。
OBJECTIVE: To investigate the transcriptional expression of SHP-1 and JAK1 genes in naive acute leukemia (AL) cells and their relationship with the chemotherapeutic effect of naive AL patients. Methods: The mRNA expressions of SHP-1 and JAK1 in 60 mononuclear cells from 20 AL patients and 20 healthy controls were detected by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). Results: The positive rates of SHP-1 and JAK1 mRNA in 60 AL patients were 30% and 100%, respectively. The expression of SHP-1 mRNA in AL patients was significantly lower than that in normal controls (P <0.001) (P = 0.180). The complete remission (CR) rate of induction chemotherapy in SHP-1 mRNA positive group was 88.9%, the CR rate of negative group was 54.8%, the difference was statistically significant (P = 0.005). There was a negative correlation between SHP-1 and JAK1 mRNA expression (P = 0.046). Conclusion: SHP-1 may be a potential suppressor of leukemia, which may be used as an indicator to evaluate the efficacy and prognosis of patients with newly diagnosed acute leukemia.